INS and Insulin resistance: The results of the clinical trial showed that sitagliptin exerted pharmacological effects such as promoting insulin secretion (6), inhibiting islet β cell apoptosis (45), improving insulin resistance (46), anti-inflammatory (47), anti-oxidative stress (48), and anti-fibrosis (49).